BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

Core Insights - BioRestorative Therapies, Inc. has achieved a significant intellectual property milestone with the Japanese Patent Office issuing a Notice of Allowance for its ThermoStem platform, which focuses on stem cell-based therapies for obesity and metabolic disorders [1][2] Company Developments - The newly allowed patent provides broad protection for BioRestorative's allogeneic, off-the-shelf brown adipose-derived stem cell (BADSC) technology, covering therapeutic cells and various methods of encapsulation and delivery [2] - This patent strengthens BioRestorative's position in developing next-generation, cell-based alternatives to GLP-1 drugs, which are rapidly growing in the therapeutic market [3][4] - The CEO of BioRestorative highlighted that the patent allowance validates the progress made with ThermoStem and positions the company favorably in the commercial landscape, especially as discussions with potential strategic partners continue [4] Market Context - The global obesity market is projected to exceed $100 billion annually by the end of the decade, driven by demand for GLP-1 therapies, which BioRestorative aims to address with its ThermoStem platform [4] - BioRestorative's ThermoStem platform is designed to provide an alternative to chronic GLP-1 injections, mitigate muscle loss, and reduce cardiovascular risks associated with current therapies [6] Clinical Programs - BioRestorative is developing two core clinical programs: - The Disc/Spine Program (brtxDISC) focuses on a cell therapy candidate, BRTX-100, for treating lumbosacral disc disorders and has commenced a Phase 2 clinical trial [5] - The Metabolic Program (ThermoStem) targets obesity and metabolic disorders using BADSC to generate brown adipose tissue, with initial preclinical research indicating potential benefits in caloric burning and metabolic regulation [6][7] Commercial Initiatives - BioRestorative operates a BioCosmeceutical platform, offering a cell-based secretome product aimed at cosmetic applications, with plans to expand its offerings in the aesthetic product space [8]